Ocugen Inc (OCGN) - Total Assets
Based on the latest financial reports, Ocugen Inc (OCGN) holds total assets worth $56.91 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Ocugen Inc (OCGN) share price today for real-time trading data and today's change.
Ocugen Inc - Total Assets Trend (2012–2025)
This chart illustrates how Ocugen Inc's total assets have evolved over time, based on quarterly financial data. Also see OCGN cash generation efficiency for how efficiently the company converts equity into cash flow.
Ocugen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ocugen Inc's total assets of $56.91 Million consist of 55.9% current assets and 44.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Ocugen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore OCGN working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ocugen Inc's current assets represent 55.9% of total assets in 2025, a decrease from 71.7% in 2012.
- Cash Position: Cash and equivalents constituted 42.7% of total assets in 2025, down from 69.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Ocugen Inc Competitors by Total Assets
Key competitors of Ocugen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $35.32 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
USA | $1.15 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.77 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Ocugen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.86 | 2.60 | 25.13 |
| Quick Ratio | 1.86 | 2.60 | 24.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.84 Million | $27.08 Million | $116.79 Million |
Ocugen Inc - Advanced Valuation Insights
This section examines the relationship between Ocugen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 69.40 |
| Latest Market Cap to Assets Ratio | 9.49 |
| Asset Growth Rate (YoY) | -47.2% |
| Total Assets | $43.52 Million |
| Market Capitalization | $413.00 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Ocugen Inc's assets at a significant premium (9.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Ocugen Inc's assets decreased by 47.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ocugen Inc (2012–2025)
The table below shows the annual total assets of Ocugen Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $43.52 Million | -47.22% |
| 2024-12-31 | $82.44 Million | +27.72% |
| 2023-12-31 | $64.55 Million | -40.58% |
| 2022-12-31 | $108.63 Million | +2.71% |
| 2021-12-31 | $105.76 Million | +286.33% |
| 2020-12-31 | $27.38 Million | +62.88% |
| 2019-12-31 | $16.81 Million | -3.56% |
| 2018-12-31 | $17.43 Million | +57.93% |
| 2017-12-31 | $11.04 Million | -69.41% |
| 2016-12-31 | $36.08 Million | -1.92% |
| 2015-12-31 | $36.79 Million | -43.84% |
| 2014-12-31 | $65.50 Million | +342.68% |
| 2013-12-31 | $14.80 Million | -29.69% |
| 2012-12-31 | $21.04 Million | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more